Related Experiment Video
Updated: Sep 9, 2025
08:45
Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes
Published on: May 10, 2022
2.1K
First-trimester medication abortion: anemia and blood loss
Lucy Rose1, Sarah Putnam2, Eve Espey1
1Department of Obstetrics and Gynecology, University of New Mexico.
Current Opinion in Obstetrics & Gynecology
|September 2, 2025
Summary
Medication abortion is safe for most, but data on its use in anemic individuals is limited. More research is needed to establish safe hemoglobin levels and improve access to care for all.
Area of Science:
- Reproductive Health
- Hematology
- Medical Guidelines
Background:
- Medication abortion is widely used and proven safe and effective.
- Limited data exists on the safety of medication abortion for individuals with anemia.
- Quantitative blood loss data from medication abortion is scarce.
Purpose of the Study:
- To review current guidelines and literature on anemia and blood loss in medication abortion.
- To inform clinical practice and future research regarding medication abortion in anemic individuals.
Main Methods:
- Literature review of current guidelines and studies on medication abortion.
- Analysis of reported blood loss in medication abortion studies.
- Examination of hemoglobin levels and gestational duration in study populations.
Main Results:
- Current guidelines lack established safe hemoglobin thresholds for medication abortion.
- Studies show minimal hemoglobin decrease (0.1-0.7 g/dl) in medication abortion.
- Most studies exclude individuals with significant anemia or later gestational durations.
Conclusions:
- Anemia disproportionately affects populations facing abortion restrictions.
- Arbitrary hemoglobin cutoffs in guidelines create barriers to care.
- Further research is needed on medication abortion safety in moderate-to-severe anemia and beyond 63 days gestation.
Related Concept Videos
01:07Teratogenicity
2.7K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.7K
01:19Rh Blood Group
1.8K
The Rhesus (Rh) antigen is crucial in determining blood groups and ensuring compatibility during blood transfusions.
1.8K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
889
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
889
01:27Ovarian Cycle
1.8K
The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle...
1.8K
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
597
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
597
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
321
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
321